This content is for informational purposes only and is not a substitute for professional advice.
CoQ10 and PQQ should be tested as slow, conservative energy experiments, not as instant fixes for fatigue. Start with dose-window discipline, one primary outcome, and a review plan that can separate a supplement signal from sleep debt, training load, caffeine drift, or wishful thinking.
This guide is for adults testing perceived energy, training quality, and recovery patterns. It is not treatment advice for fatigue syndromes, mitochondrial disorders, cardiovascular disease, neurologic disease, statin side effects, anemia, thyroid disease, sleep apnea, depression, pregnancy, or any new, severe, persistent, or unexplained fatigue.
Why this trial needs restraint
CoQ10 has a wider human evidence base than PQQ, especially in clinical contexts outside general wellness. PQQ has mechanistic interest and smaller human studies, yet most product claims run ahead of the evidence. That makes the testing standard stricter: choose one compound first, keep the rest of the stack still, and judge only outcomes that can plausibly move over weeks.
For general energy, the cleanest question is not "do mitochondria feel better?" The cleaner question is whether a stable dose produces a measurable change in afternoon fatigue, training completion, perceived exertion, or recovery rating after enough exposure time.
Protocol table
| Phase | Window | What to do | Decision rule |
|---|---|---|---|
| Baseline | 14 days | No new energy supplements. Log fatigue, sleep, training, recovery, caffeine, alcohol, and meal timing. | Continue only if baseline logging is at least 80% complete. |
| Active | 4 to 8 weeks | Test CoQ10 or PQQ, not both. Use the same brand, dose, form, and meal timing every day. | Look for a sustained change from baseline, not a single good week. |
| Optional add-on | 4 to 8 more weeks | If CoQ10 was tolerated and useful, add PQQ as a separate second phase. | Treat the second phase as a new experiment. |
| Washout | 14 to 28 days | Stop the tested compound and keep logging the same metrics. | A useful signal should weaken or disappear after removal. |
| Review | 1 day | Compare baseline, active, and washout averages. | Continue only if benefit is meaningful, repeatable, and worth the cost and burden. |
Baseline window
Run a 14-day baseline before adding either supplement. Shorter baselines are weak for fatigue because training stress, work stress, sleep timing, menstrual cycle phase, travel, alcohol, and caffeine can swing energy ratings more than the supplement being tested.
Record the same entries at the same time each day. Morning energy belongs in the morning. Afternoon slump belongs in the afternoon. Recovery belongs after waking and again after training if you train that day.
| Baseline field | How to log it | Why it matters |
|---|---|---|
| Morning energy | 1 to 10 within 30 minutes of waking | Captures sleep carryover before caffeine distorts the signal |
| Afternoon fatigue | 1 to 10 between 2 PM and 5 PM | Main subjective endpoint for non-stimulant energy |
| Training readiness | 1 to 10 before training | Separates motivation from actual session quality |
| Session RPE | 1 to 10 after training | Detects whether the same work feels easier |
| Recovery | 1 to 10 the morning after training | Captures soreness, heaviness, and readiness to repeat work |
| Sleep duration and quality | Hours plus 1 to 10 quality | Fatigue data without sleep data is rarely interpretable |
| Caffeine | Total mg and final dose time | Late or rising caffeine can fake an energy benefit |
Active window
Start with one compound. CoQ10 is usually the more defensible first test because its human literature is larger and dose formats are clearer. PQQ can be tested later if the CoQ10 phase is stable or if there is a specific reason to prefer PQQ.
Use a single-ingredient product with a transparent label. Take it with a consistent meal, since CoQ10 is fat-soluble and food context can affect exposure. Do not add a new pre-workout, adaptogen, B-complex, thyroid support product, iron, or "mitochondria complex" during the trial.
| Choice | Conservative testing rule |
|---|---|
| CoQ10 | Use one form, one daily dose, and meal-consistent timing for 4 to 8 weeks. |
| PQQ | Use one PQQ product at the label dose for 4 to 8 weeks after baseline. |
| CoQ10 plus PQQ | Do not start together. Add the second only after reviewing the first. |
| Combination formulas | Avoid for testing because attribution becomes weak. |
Metrics
The primary endpoint should be one fatigue or function metric chosen before the trial starts. Pick the metric that would make the supplement worth continuing if it improved.
| Metric | Better signal | Weak signal |
|---|---|---|
| Afternoon fatigue | Average improves by at least 1 point for 2 or more active weeks | One unusually good day |
| Training completion | More planned sessions completed without higher caffeine | More motivation paired with worse sleep |
| Session RPE | Same workout feels easier at similar load and duration | Easier workout because volume dropped |
| Recovery rating | Morning-after recovery improves after comparable sessions | Recovery improves during a deload week |
| Resting heart rate | Stable or lower versus baseline | Higher rate, palpitations, or worse sleep |
Avoid turning every wearable field into an endpoint. Heart rate variability, sleep staging, strain scores, and readiness scores can help with context, yet they should not replace the prespecified outcome.
Confounders
The trial is only useful if the main confounders are controlled tightly enough to leave room for interpretation.
| Confounder | Control rule |
|---|---|
| Caffeine | Keep total daily caffeine and final dose time within a narrow range. |
| Training load | Mark deload weeks, hard blocks, races, and unusually long sessions. |
| Sleep timing | Keep bedtime and wake time close to baseline, or flag the day. |
| Calories and carbohydrate | Mark under-fueled days and low-carb training days. |
| Alcohol | Log any alcohol because it can distort sleep and recovery. |
| New supplements | Do not add or remove other energy, sleep, thyroid, iron, or adaptogen products. |
| Medication changes | Pause interpretation and ask a clinician or pharmacist when medication context changes. |
Stop criteria
Write stop criteria before the first dose. Fatigue experiments invite motivated reasoning because improvement is easy to want and hard to measure.
| Stop signal | Action |
|---|---|
| Rash, swelling, wheezing, or allergic symptoms | Stop immediately and seek appropriate care. |
| Palpitations, chest pain, fainting, or severe dizziness | Stop and seek urgent medical review. |
| Insomnia or sleep quality drop for 3 or more nights | Stop or end the phase early. |
| GI distress lasting more than 3 days | Stop, then review dose, timing, and product quality. |
| Resting heart rate 10 or more bpm above baseline for 3 days | Stop and review caffeine, illness, training, and medication context. |
| Warfarin, anticoagulant use, chemotherapy, blood-pressure medication, or complex cardiovascular history | Do not self-test without clinician or pharmacist guidance. |
Time-to-signal
Do not judge CoQ10 or PQQ like caffeine. A same-day lift is more likely to be expectancy, better sleep, meal timing, or normal day-to-day variance. The planned active window is 4 to 8 weeks because the useful question is whether a pattern holds across repeated workdays and training sessions.
A reasonable review schedule is week 2 for tolerability, week 4 for early signal, and week 8 for the main decision. If there is no meaningful movement by week 8, continuing indefinitely is usually a belief decision rather than a data decision.
Unfair workflow
Create a dedicated experiment in Unfair named "CoQ10 energy test" or "PQQ energy test." Set the baseline window to 14 days, then define the active window with the exact product, form, dose, dose time, and meal context. Add stop rules before the first active dose.
Track one primary endpoint and two secondary endpoints. For example: afternoon fatigue as primary, training completion and recovery rating as secondary. Tag confounders daily instead of editing them from memory at the end of the trial.
At review, compare baseline, active, and washout averages. Keep the supplement only if the benefit is large enough to survive confounder review and meaningful enough to justify the cost. If the active phase improves but the washout does not worsen, mark the result as uncertain rather than successful.
Sources
This article is for education only and does not replace medical advice.
NIH National Center for Complementary and Integrative Health. Coenzyme Q10. https://www.nccih.nih.gov/health/coenzyme-q10
↩Tsai IC, Hsu CW, Chang CH, Tseng PT, Chang KV. Effectiveness of Coenzyme Q10 Supplementation for Reducing Fatigue: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Front Pharmacol. 2022. https://pmc.ncbi.nlm.nih.gov/articles/PMC9449413/
↩Harris CB, Chowanadisai W, Mishchuk DO, et al. Dietary pyrroloquinoline quinone alters indicators of inflammation and mitochondrial-related metabolism in human subjects. J Nutr Biochem. 2013. https://pubmed.ncbi.nlm.nih.gov/23830056/
↩Bhagavan HN, Chopra RK. Coenzyme Q10: Absorption, tissue uptake, metabolism and pharmacokinetics. Free Radic Res. 2006. https://pubmed.ncbi.nlm.nih.gov/16551570/
↩Vohra S, Shamseer L, Sampson M, et al. CONSORT extension for reporting N-of-1 trials. BMJ. 2015. https://www.bmj.com/content/350/bmj.h1738
↩